Amplicon sequencing is a next generation sequencing (NGS) technique used to detect low frequency variants, quantify mixed populations, and analysis multiple samples at scale.
We offer various solutions for ultra-deep amplicon sequencing of PCR products to validate and discover variations in specific genomic regions or screen clones. Our amplicon sequencing services employ the latest technologies for custom, in-depth analysis of amplicons ranging from 100 base pairs (bp) to >10,000 bp.
Applications for amplicon sequencing include antibody library screening, natural antibody repertoire profiling, disease genotyping, CRISPR mutation analysis, 16S and 18S amplicon sequencing, screening of molecular clones, and analysis of plasmid stocks.
Amplicon sequencing is a targeted sequencing method that uses polymerase chain reaction (PCR) to selectively amplify specific DNA fragments or genomic regions of interest. Specific primers are designed to flank the target region and the resulting amplicons are then sequenced to determine the nucleotide sequence.
Targeted sequencing and amplicon sequencing both selectively sequence specific regions of the genome, rather than the whole genome. However, the difference between the two methods lies in how the regions of interest are selected and amplified.
Targeted sequencing amplifies through hybridization capture and uses probes or baits complimentary to the target region in order to selectively capture and enrich for specific genomic regions, such as genes, exons, and other functional regions of the genome. Targeted sequencing often offers greater coverage than amplicon sequencing, as the use of hybridization capture can help mitigate biases in the representation of certain genomic regions.
Amplicon sequencing amplifies DNA fragments using PCR. The target regions are defined by PCR primers designed to anneal specific sequences that flank the areas of interest, initiating the amplification process of the targeted DNA fragments. Amplicon sequencing is often more cost-effective than targeted sequencing as it does not involve the use of capture reagents.
Multiple Solutions to Answer Every Biological Question
Azenta's Recommendation | ||||
Amplicon Size | Applications | Library Preparation Type | Platform Configuration | |
100-250 bp |
|
Adapter ligation to |
Illumina 2x150 bp | |
250-550 bp |
|
Adapter ligation to full-length products |
Illumina 2x250 bp or 2x300 bp |
|
|
Fragmentation | Illumina 2x150 bp | ||
>550 bp |
|
Adapter ligation to full-length products |
PacBio Sequel | |
|
Fragmentation | Illumina 2x150 bp |
A biopharma company required a partner for clinical trial support, with an immediate need for development and validation of a biomarker assay using next generation sequencing with a quick turnaround time. Read the case study to learn how this company was able to streamline clinical testing and accelerate the timeline of its phase 1/2 study.
This selection guide offers practical information about PCR + Sanger, qPCR, and NGS approaches to help you determine which assay best suits your project requirements, along with an interactive assay selection tool to aid your decision making.
Azenta accepts purified and unpurified amplicons, restriction digested material, fragmented DNA, and plasmids. For detailed sample submission requirements please visit our Sample Submission Guidelines.
For information on our NGS platforms as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.